Related Experiment Videos
MR findings in methotrexate-induced CNS abnormalities.
1Department of Radiology, Karl-Franzens-University Graz, Medical School, Austria.
AJNR. American Journal of Neuroradiology
|September 1, 1989
Summary
Magnetic resonance imaging (MRI) can detect brain abnormalities in osteogenic sarcoma patients treated with high-dose methotrexate. These findings, including edema and necrosis, correlate with neurological dysfunction.
Area of Science:
- Neurology
- Radiology
- Oncology
Background:
- Osteogenic sarcoma treatment often involves high-dose methotrexate, a chemotherapy agent with potential neurotoxicity.
- Monitoring central nervous system (CNS) effects is crucial for patients undergoing such treatments.
Observation:
- Brain magnetic resonance imaging (MRI) was conducted on eight pediatric patients with osteogenic sarcoma receiving high-dose methotrexate.
- The study aimed to identify treatment-induced brain abnormalities and their correlation with neurological symptoms.
Findings:
- MRI revealed brain abnormalities in four patients (50%).
- Three of these four patients exhibited concurrent neurological dysfunction.
- Specific findings included chronic brain edema, multifocal white matter necrosis, and deep brain atrophy.
Implications:
- MRI is a valuable tool for detecting methotrexate-induced neurotoxicity in osteogenic sarcoma patients.
- Early detection of these abnormalities may allow for timely intervention and management of neurological complications.
- Further research can explore the long-term effects and optimal imaging protocols for monitoring neurotoxicity.